Haemonetics (HAE) PT Raised to $77 at Morgan Stanley
Morgan Stanley raised its price target on Haemonetics (NYSE: HAE) to $77.00 (from $74.00) while maintaining a Overweight rating.
Morgan Stanley raised its price target on Haemonetics (NYSE: HAE) to $77.00 (from $74.00) while maintaining a Overweight rating.